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Abstract 
Melanoma involving the conjunctiva is extremely rare. Graver prognosis has been 
reported with primary conjunctival melanoma than with their cutaneous counterparts 
[Collin et al.: Aust N Z J Ophthalmol 1986;14:29–34]. Among conjunctival melanomas, 
two significant risk factors for tumour-related death have been identified: (i) age older 
than 55 years and (ii) unfavourable tumour location (caruncle, cornea, fornix, palpebral 
conjunctiva) [Werschnik and Lommatzsch: Am J Clin Oncol 2002;25:248–255]. Here we 
present a rare case of lentigo maligna involving the palpebral, bulbar conjunctiva and 
the caruncle. We describe dermoscopic patterns observed and the use of a novel ocular 
melanoma therapy with topical imiquimod. 
 
Case Report 
A 74-year-old man was referred to our Department with an asymptomatic lesion located in the 
bulbar conjunctiva since childhood. He reported that the lesion had grown fast during the last months, 
presenting with diffuse pigment clusters involving the tarsal, bulbar and lower palpebral conjunctiva of 
the right eye and caruncle. The patient was a Fitzpatrick phototype II and his clinical history was 
relevant for multiple actinic keratosis and a parotideal epidermoid carcinoma. 
On physical examination, the patient had several ill-defined, small brown and black macules located 
in the bulbar, palpebral and tarsal conjunctiva and the caruncle (fig. 1). The dermoscopic study showed 
peppering, globules and dots distributed in a parallel pattern in the tarsal and marginal conjunctiva and 
dilated vessels in the bulbar conjunctiva. Pigmented blotches in the caruncle were observed.  
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Polychromia was also evident, with the presence of black, light brown, dark brown and grey colours. 
Dilated vessels with a rope-ladder pattern in the palpebral conjunctiva were observed (fig. 2, fig. 3). The 
parallel conformation found in our patient may correspond to the dendritic distribution of the 
melanocytes between the keratinocytes in the epithelium. The rope-ladder pattern observed in the 
palpebral conjunctiva could reflect the vessels crossing the dense fibrous stroma of the tarsus. 
Incisional biopsies were performed. Microscopic review of the specimens demonstrated an atypical 
proliferation of melanocytes in a lentiginous pattern. Melanocytes showed a pagetoid distribution 
between the keratinocytes in the epithelium. Immunohistochemical stains were positive for S-100, 
Melan-A and HMB-45. Ki-67 was weakly positive (fig. 4, fig. 5). 
After histopathological confirmation of lentigo maligna (LM), the patient underwent treatment by 
excisional biopsy of the larger lesions and adjuvant cryotherapy resulting in no visibly apparent disease. 
Histopathological analysis of the specimen confirmed the previous diagnosis of LM. A total body 
PET/CT scan was negative for distant metastasis. Routine blood tests were in normal ranges. These 
examinations resulted in the diagnosis of an AJCC-UICC stage of T1; N0, M0. 
Due to the multifocal distribution of the tumour, adjuvant topical mitomycin C was added (0.04%, 
four times daily) during 3 months. Topical imiquimod (IMQ) 5% cream (250 mg) was started in the 
caruncle area once daily, five times per week. Weekly follow-up was achieved. The patient experienced 
temporal conjunctival and cutaneous irritation and eyelid oedema, but this was alleviated by artificial 
tears and lubricating ointment and the therapy was continued. No systemic side effects were noted. He 
completed a 6-week course of IMQ therapy that resulted in complete regression of the caruncle lesion. 
One year after completion of therapy, he remains disease-free clinically and pathologically (fig. 6). 
Discussion 
The decisive diagnosis procedure in conjunctival melanoma is the histological 
examination [1–4]. Dermoscopy is a noninvasive technique that can help us to 
distinguish between benign and malignant lesions. Histological findings and the 
differences between benign and malignant conjunctival lesions [5, 6], even the correlation 
with confocal microscopy [7, 8] have been described in the literature. Nevertheless, only 
one manuscript describes digital surface microscopy parameters to evaluate these lesions 
[7]. They suggest four categories for evaluating the lesions: geometry (area, maximum and 
minimum diameter), colour, texture and islands of colour. Higher values in geometry, 
darker colour and predominance of blue colours, higher contrast and the imbalance of 
blue-grey regions are suggestive of melanoma. 
The three most common forms of melanoma described in the skin are: (1) LM, (2) 
superficial spreading melanoma, and (3) nodular melanoma. These forms can also be 
recognized in the conjunctiva. As in the skin, LM appears to be associated with a good 
prognosis compared to the prognosis associated with superficial spreading of melanoma. 
These two forms of melanoma are both associated with an intraepithelial stage and had 
previously been grouped under one designate, cancerous melanosis [6–9]. They can be 
distinguished histologically although definite clinical differentiation is to be determined 
in the future. Dermoscopy could add an interesting tool to this field. 
Surgical excision is the gold standard for melanoma; however, because lesions are often 
quite large or involving sensitive areas such as the eyelid, extensive surgery could produce 
cosmetic deformity and functional disability [8, 9]. Possible therapeutic approaches to this 
condition are exenteration of the orbit, excision combined with cryotherapy, and excision 
combined with radiotherapy [8]. Nonsurgical options include cryotherapy, topical 
mitomicin or interferon. IMQ is a topical immunomodulator available in a 5% cream that 
can generate a local cytotoxic response with potentially antiviral and antitumor effects. 
IMQ is approved for the treatment of genital warts, actinic keratosis and superficial basal 
cell carcinomas. Off-label uses include: mycosis fungoides, Bowen’s disease and LM [10].  
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Topical IMQ 5% cream is a valid option for patients with comorbid conditions, lesions 
located in sensitive areas or extensive lesions that may discourage surgery. Patients may 
experience constitutional symptoms, punctate keratopathy or diminished visual acuity as 
side effects associated with cytokine release, but these should resolve if the treatment is 
discontinued [11]. Although these results are relatively short-term, the findings suggest 
that IMQ topical therapy could be considered as an adjuvant therapy in cases of caruncle 
involvement in ocular LM and melanoma in situ. We consider IMQ as an option in the 
treatment of patients in whom surgery may be contraindicated or for those in whom the 
cosmetic or functional consequences would be considerable, like our patient. 
Most importantly, the patient needs to be aware that it is an off-label use and the long-
term effectiveness of this treatment has not been proven. 
 
 
 
 
 
Fig. 1. Several ill-defined, millimetric brown and black macules located in the bulbar, palpebral and 
tarsal conjunctiva and the caruncle could be observed. 
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Fig. 2. Light and dark brown globules and dots could be observed in a parallel pattern. Brown blotches 
and arborizing vessels in the palpebral and bulbar conjunctiva were also found. 
 
 
 
Fig. 3. Red and gray colours were present mostly in the tarsal conjunctiva. Vessels with a rope-ladder 
pattern (scar-like) were found. 
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Fig. 4. Histopathological examination revealed atypical proliferation of melanocytes in a lentiginous 
pattern. Melanocytes showed a pagetoid distribution between the keratinocytes in the epithelium. 
 
 
 
Fig. 5. Melanocytic marker Melan-A expression was consistent with LM in immunohistochemical 
studies. 
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Fig. 6. One-year follow-up showed the patient was disease-free. 
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